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Protein kinase C iota (PKCι), a serine/threonine kinase required 
for cell polarity, proliferation and migration, is commonly up- or 
downregulated in cancer. PKCι is a human oncogene but whether 
this is related to its role in cell polarity and what repertoire of 
oncogenes acts in concert with PKCι is not known. We developed a 
panel of candidate oncogene expressing Madin–Darby canine kid-
ney (MDCK) cells and demonstrated that H-Ras, ErbB2 and phos-
phatidylinositol 3-kinase transformation led to non-polar spheroid 
morphogenesis (dysplasia), whereas MDCK spheroids expressing 
c-Raf or v-Src were largely polarized. We show that small inter-
fering RNA (siRNA)-targeting PKCι decreased the size of all 
spheroids tested and partially reversed the aberrant polarity phe-
notype in H-Ras and ErbB2 spheroids only. This indicates distinct 
requirements for PKCι and moreover that different thresholds of 
PKCι activity are required for these phenotypes. By manipulating 
PKCι function using mutant constructs, siRNA depletion or chem-
ical inhibition, we have demonstrated that PKCι is required for 
polarization of parental MDCK epithelial cysts in a 3D matrix and 
that there is a threshold of PKCι activity above and below which, 
disorganized epithelial morphogenesis results. Furthermore, 
treatment with a novel PKCι inhibitor, CRT0066854, was able 
to restore polarized morphogenesis in the dysplastic H-Ras sphe-
roids. These results show that tightly regulated PKCι is required 
for normal-polarized morphogenesis in mammalian cells and that 
H-Ras and ErbB2 cooperate with PKCι for loss of polarization and 
dysplasia. The identification of a PKCι inhibitor that can restore 
polarized morphogenesis has implications for the treatment of Ras 
and ErbB2 driven malignancies.
Introduction
Protein kinase C iota (PKCι) is a serine/threonine kinase and an atypi-
cal member of the PKC family (aPKC), which is overexpressed and 
correlated with prognosis in a number of human malignancies (1–9). 
Several groups have reported anticancer effects of aPKC inhibitors 
although the mechanisms for this have not been fully elucidated 
(10–12). aPKC plays an important role in promoting apicobasal polar-
ity of cells, mitotic spindle orientation, directional cell migration and 
epithelial barrier function; these functions are conserved from model 
organisms (Caenorhabditis elegans and Drosophila melanogaster) to 
humans (13–17).
The ‘atypical’ nomenclature of aPKC refers to the divergent regu-
latory domain compared with classical and novel PKCs in that it 
lacks a C2 domain and has an altered, DAG-insensitive C1 domain. 
Instead, aPKC has an N-terminal PB1 domain that interacts with 
the Par6-cdc42-GTP complex and probably, like other PKCs, the 
upstream regulatory domain interactors lead to allosteric activation 
by release of an inhibitory intramolecular interaction between the 
regulatory domain and the substrate-binding site (18,19). Activity 
also requires priming phosphorylations of the activation loop 
(T403/410) and turn motif (T555/556) by the upstream kinases, 
PDK1 (20) and likely TORC2, respectively (21,22). By analogy to 
other PKCs, nucleotide pocket occupation is likely to be important 
for determining the upstream kinase/phosphatase balance (23,24). 
However, beyond this the acute inputs that lead to activation of 
aPKC are poorly defined.
Cell polarity refers to the restriction of cellular components to 
particular regions of the cell (25,26). In epithelial monolayers, tight 
junctions form the boundary between the apical membrane surface 
and the basal membrane domain and with additional junctional com-
plexes (adherens junctions) comprise the cell–cell contacts (27–29). 
Maintenance of these cell–cell contacts contributes to the survival of 
cells (release of normal epithelial cells from the monolayer causes 
anoikis) (30), to a restraint on proliferation through contact inhibition 
and to appropriate apical/basolateral receptor distribution and hence 
receptor-driven responsiveness (31,32).
Deregulation of polarity proteins is often associated with a more 
invasive phenotype in tumour model systems (33,34), and loss of 
apical–basal polarity in human epithelial cells is one of the hall-
marks of aggressive and invasive cancers (35–37). Results from 
genetic screens in D.melanogaster suggest that aberrant expression 
of certain polarity genes (scrib, lgl and Crb) can lead to hyperplas-
tic tumour formation in a wild-type (WT) background, whereas in 
an oncogenic Ras or Notch background they lead to invasive and 
metastatic tumours (38–41). Transgenic mouse studies have recently 
shown that deletion of the genes for Par4/LKB1 or Par3, two well-
recognized polarity proteins, can contribute to tumour formation 
(32,42,43).
A number of studies have demonstrated physical and/or functional 
interactions between aPKC and bona fide human oncogenes such 
as phosphatidylinositol 3-kinase (PI3K) (44,45), Ras (46–49), Raf 
(50), ErbB2 (51) and Src (52,53). Equally, aPKC has been implicated 
genetically and through its ex vivo manipulation in the establishment 
and maintenance of polarity (54–56). However, it is quite unclear 
what the relationship is between the opposing aPKC functions of 
polarization and proliferation.
Madin–Darby canine kidney (MDCK) cells embedded in collagen 
matrix gels have been shown to form cysts that broadly recapitulate 
the morphological features of the renal collecting ducts from which 
they derive (57–59). As the cyst forms, there is central apoptosis, 
lumen formation (lumenogenesis) and localization of distinct pro-
teins at the apical (facing lumen) or basal (facing outwards) plasma 
membranes. Suppression of aPKC, by RNA interference or domi-
nant-negative constructs, has been shown to induce misorientation 
of the mitotic spindle, mispositioning of the nascent apical surface 
and ultimately the formation of aberrant cysts with multiple lumens 
(60–62).
Here, we have tested the relationship between the requirement 
for PKCι in the polarized morphology of MDCK cells and its role 
Abbreviations: aPKC, atypical protein kinase C; cDNA, complementary 
DNA; GFP, green fluorescent protein; MDCK, Madin–Darby canine kidney; 
PBS, phosphate-buffered saline; PI3K, phosphatidylinositol 3-kinase; PKCι, 
protein kinase C iota; PSAL, predominant single apical lumen; siRNA, small 
interfering RNA; WT, wild-type.
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in response to well-recognized human oncogenes that lead to altered 
epithelial morphology (51,63). Exploiting the MDCK cell model, 
we find that PKCι is required for the abnormal morphology caused 
by activated H-Ras and ErbB2, but not activated PI3K. This require-
ment appears to be a consequence of overactive PKCι since titra-
tion of PKCι function by small interfering RNA (siRNA) or with 
an aPKC-selective catalytic inhibitor partially corrects the abnormal 
H-Ras-induced morphology. All transformed derivatives displayed 
reduced proliferation on PKCι knockdown. Notably, PKCι displays a 
threshold behaviour with too little or too much activity causing loss of 
polarized organisation (dysplasia). These results implicate PKCι as a 
good therapeutic target in a subset of malignancies.
Materials and methods
Reagents
Reagents were purchased from Sigma unless otherwise specified. Mouse 
monoclonal PKCλ (610208), β-catenin (610154), GM130 (610823) and c-Raf 
(610151) antibodies were obtained from BD Biosciences. Rabbit monoclonal 
Her2 (2165) and rabbit polyclonal pPKCζ/λ (T410/403) (9378), pSrc (Y416) 
(2101), pSrc (Y527) (2105) antibodies were obtained from Cell Signaling. 
Rabbit polyclonal ZO-1 (40–2200) and pPKCι (T555) (44-968G) antibod-
ies were obtained from Invitrogen. Alexa-555 goat anti-rabbit (A21429), 
Alexa-555 goat anti-mouse (A21422), Alexa-488 goat anti-mouse (A11001), 
Alexa-488 goat anti-rabbit (A11008) and Alexa-680 goat anti-rabbit (A21109) 
secondary antibodies were from Invitrogen. IR dye 800 goat anti-mouse 
(926-3221G) secondary antibody was from LI-COR Biosciences. IgG 
F(ab′)2 Goat anti-mouse blocking antibody (115-007-003) was from Jackson 
ImmunoResearch Labs. Go6983 was from Calbiochem and CRT0066854 was 
a gift from Cancer Research Technology.
Plasmids
Human PKCι complementary DNA (cDNA) (gifted from T.Biden) was sub-
cloned into pEGFP-C1 vector (Clontech) incorporating a 5′-Myc-tag sequence 
and using 5′-SalI and 3′-BamHI restriction sites. The Entrez Nucleotide acces-
sion number is NM_002740.5. The cDNA contains two start codons at bp1-3 
and bp28-30 with the second methionine denoted as the first amino acid of the 
protein. Green fluorescent protein (GFP)-PKCι mutants were generated using 
the QuikChange system (Stratagene). ErbB2-YVMA in a pEGFP-N1(A206K) 
vector was a gift from Tony Ng (Kings College London, UK).
siRNA and transfection
Transient reverse transfections of cDNA for MDCK cells were performed 
on Poly-l-lysine precoated plates using Lipofectamine 2000 as per the 
manufacturer’s instructions (Invitrogen). siRNA reverse transfections of 
MDCK were performed using Lullaby (Oz Biosciences) and Poly-l-Lysine 
precoated plates. For a 6-well plate, 25 nM siRNA and 10μl Lullaby were 
mixed together in Optimen, incubated for 20 mins and added to 2–3 × 105 
cells per well. Media was refreshed at 20 h and typically further manipula-
tion took place 72 h posttransfection. Rescue experiments were performed by 
sequential transfection, initially using siRNA, as above, and then after 24 h 
cells were transfected using Lipofectamine 2000 and the appropriate cDNA. 
Knockdown efficiency was analysed by western blot and immunostain-
ing of PKCι compared with the α-tubulin loading control. Target sequences 
for canine PKCι were 5′-AGTTCTGTTGGTGCGATTA-3′ (cfPKCι.1) 
and 5′-AAGCTCTGATAACCCGGATCA-3′ (cfPKCι.2) and scrambled 
controls were 5′-AATGAGTGAGTAGTCTTTGCT-3′ (cfSCRAM.1) 
and 5′-AAGGCCCAACGAAACCATACA-3′ (cfSCRAM.2).
Cell culture and stable cell lines
MDCK cells were obtained from Cell Production, Cancer Research UK. 
Isoenzyme and single nucleotide polymorphism analysis was performed by 
cell services to authenticate the origin of these cells. Cells were maintained in 
Dulbecco’s modified Eagle’s medium supplemented with 10% foetal bovine 
serum and PenStrep at 37°C in a humidified 5% CO2 atmosphere. Stable 
MDCK cell lines expressing V12-Ras, p110-CAAX, v-Src or Raf-CAAX have 
been described previously (63). Stable ErbB2-MDCK cells were generated by 
liposomal transfection followed by selection with 750 g/ml G418 (GIBCO). 
These polyclonal cell lines were further selected based on moderate to high 
GFP expression by two successive rounds of fluorescence-activated cell sort-
ing (CRUK FACS facility).
Three-dimensional lumenogenesis assay
The 3D culture of MDCK cells in Matrigel was performed as described pre-
viously (57,59,64). In brief, cells in log phase growth were trypsinized and 
resuspended in standard media supplemented with 2% low growth factor 
Matrigel (BD) at 2 × 104 cells/ml. Each well of an 8-well chamber slide (BD) 
was precoated with 30 μl of 100% Matrigel to which 400 μl of the cell suspen-
sion was added. Media-2% Matrigel was changed on alternate days for 5 days.
Immunofluoresence microscopy
MDCK cysts/spheroids grown in Matrigel on chamber slides were fixed with 
2% formaldehyde in phosphate-buffered saline (PBS), washed in PBS and then 
permeabilized with 0.5% Triton X-100 in PBS. Alternatively, cysts/spheroids 
were released from Matrigel using ice-cold ethylenediaminetetraacetic acid–
PBS, attached to poly-l-lysine-coated slides by centrifugation and then fixed 
and permeabilized as for the chamber slides. Immunostaining was carried 
out as described previously (65). After a quick rinse with PBS, cultures were 
mounted with Prolong Gold hard set mounting medium (Invitrogen).
MDCK cysts that had their F-actin stained with phalloidin were visualized 
with a confocal microscope (Zeiss 510) and an apical lumen assessment made. 
The middle of a cyst in the z plane was identified and the following criteria 
applied to determine whether the cyst has a ‘predominant single apical lumen’ 
(PSAL): (i) there must have been a clear continuous F-actin-defined lumen; (ii) 
the luminal actin staining must have been more intense than the basal (outside) 
staining; (iii) the unidimensional measurement of this lumen must have been at 
least one-third of the cyst diameter and (iv) the unidimensional measurement of 
the lumen must have been at least twice the size of any other luminal structure.
Western blotting
For immunoblotting, lysates or immunoprecipitates were resolved by sodium 
dodecyl sulphate–polyacrylamide gel electrophoresis and transferred to poly-
vinylidene difluoride membranes. Immunoblots were blocked in 3% bovine 
serum albumin–Tris-buffered saline containing 0.1% Tween 20 and probed 
with primary antibodies as indicated. Following incubation with appropriate 
secondary antibodies, bands were visualized using the Odyssey infrared imag-
ing system (LI-COR Biosciences). The quantification of the bands was per-
formed using the Gel function on ImageJ version 1.40g.
Statistical analysis
Differences between the treatment groups were assessed by analysis of vari-
ance with a repeated measurement module using statistical software (GraphPad 
Prism; version 5.0d). P values of <0.05 were regarded as significant.
Results
Loss of polarity in Ras- and ErbB2-transformed MDCK cells requires 
PKCι
To assess the apparently anomalous requirement for PKCι in normal-
polarized cells and oncogene-dependent depolarized growth, we 
established an MDCK cell 3D culture model and various oncogene-
driven variants. This cell model lends itself to functional analysis 
of PKCι and circumvents the possible redundant function of PKCζ, 
the closely homologous aPKC, as there is comparatively little PKCζ 
protein in MDCK cells (56). Furthermore, cysts can form within 
6  days of culture in Matrigel (Supplementary Figure S1A, avail-
able at Carcinogenesis Online), displaying typical polarized features 
(Supplementary Figure S1B, available at Carcinogenesis Online) and 
enabling siRNA-driven knockdown and transient expression studies 
to be undertaken within this time window.
Contrary to the polarized behaviour of the parental cell line, Raf-
CAAX-, v-Src-, p110α-CAAX-, V12H-Ras- and ErbB2-transformed 
MDCK cell lines all grow in 3D culture with enlarged, aberrant or no 
overt polarization (Figure 1A). In particular, H-Ras-MDCK and p110α-
MDCK grew as large, non-polarized spherical aggregates that lacked an 
apical (central) lumen and an apical actin ring. The v-Src cells developed 
with a large central lumen surrounded by multiple smaller lumens. The 
Raf-MDCK cells formed as large but otherwise apparently normal cysts. 
As many of these structures derived from the oncogenic MDCK cell 
lines were not cysts, we refer to them as oncogenic MDCK spheroids.
In 2D culture, parental cells grew as clusters and at confluence 
adopted a characteristic cobblestone appearance (57). As a monolayer, 
the MDCK variants that expressed H-Ras, p110α and v-Src were 
more fibroblastic in appearance and lost their direct cell–cell contacts, 
an appearance most pronounced in H-Ras-MDCK cells (Figure 1A).
Each oncogene expressing MDCK cell line was shown to over-
express their defining oncogenic protein by western blot analysis 
(Figure 1B). Similar protein loading was demonstrated with tubulin 
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or the consistent phosphorylation of c-Src at tyrosine 527, a residue 
that is present in normal cellular c-Src but deleted in constitutively 
active v-Src (66). Total PKCι levels were similar between the parental 
MDCK cells and the oncogenic MDCK cell panel. Phosphorylation of 
the activation loop of PKCι at threonine 403 or the turn motif at threo-
nine 555 have been suggested as a possible markers of PKCι activity 
(67,68). However, phosphorylation at these sites were uniform for the 
parental and oncogenic MDCK cells (Figure 1C), (see Discussion).
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Fig. 1. Characterization of oncogenic MDCK cells. (A) MDCK cell variants cultured in Matrigel (3D) for 6 days alongside phase images of their growth in 2D. 
Phalloidin (red)-stained actin and Hoechst (blue)-identified nuclei. Scale bar represents 50 μm. Lysates of MDCK oncogenic variant cell lines in log phase growth 
were immunoblotted for (B) defining proteins and (C) phospho-PKCι/total PKCι.
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To further examine whether cooperation between the activated 
oncogenes and PKCι contributed to the loss of apical lumen formation 
and loss of polarity, PKCι was transiently downregulated in each of 
the oncogene expressing MDCK cell lines using two distinct canine 
PKCι-directed siRNA duplexes. From initial studies in ErbB2 sphe-
roids, it was striking that siRNA-PKCι led to reconstitution of an api-
cal lumen and apical actin staining although in most cases this did 
not lead to the appearance of a fully normal MDCK cyst. In order 
to capture these differences objectively, an alternative parameter was 
defined as PSAL (see Materials and methods). The reproducibility 
of this scoring was validated and applied to subsequent experiments.
In both H-Ras and ErbB2-MDCK spheroids, but not v-Src 
(Figure 2A and B), p110α or Raf (Supplementary Figure S2A and B, 
available at Carcinogenesis Online) expressing cells, knockdown of 
PKCι resulted in significantly more PSAL spheroids. In the p110α-
transformed spheroids, there was no difference in PSAL score between 
the siRNA-PKCι and the scrambled control, but unlike the Raf-MDCK 
spheroids, apical lumens were rarely present at all and knockdown 
was efficient (Supplementary Figure S2, available at Carcinogenesis 
Online). Upon PKCι knockdown of the parental MDCK cells, <50% 
of spheroids contained a PSAL compared with over 70% in the group 
treated with the scrambled control siRNA (Figure 2A and B). The max-
imal PKCι knockdown efficiency by the siRNA duplexes was between 
70 and 80% depending on cell line, except for Raf-expressing cells 
where the level of knockdown was consistently <40% (Figure 2C). It 
must be noted that assessment of PKCι abundance in 3D was hampered 
by a poor signal to noise when lysates were generated following cold 
ethylenediaminetetraacetic acid extraction from Matrigel and therefore 
the PKCι knockdown was monitored in the parallel 2D cultures 72 h 
post-transfection. However, we have subsequently demonstrated that 
siRNA-PKCι knockdown of parental 3D MDCK cysts closely mirrors 
the level of knockdown of 2D MDCK at 72 h posttransfection.
To determine the specificity of the siRNA utilized in these knock-
down studies, we rescued the siRNA-induced phenotype with a 
siRNA-resistant cDNA of PKCι. Human PKCι-cDNA differed from 
the homologous region of the canine siPKCι.2 by four non-consecu-
tive nucleotides and this proved to be resistant to the canine siRNA 
(Figure 3A and B). H-Ras-MDCK cells were transfected sequentially, 
first with siPKCι and then after 24 h with the human cDNA for PKCι. 
Following co-transfection of H-Ras-MDCK cells with siPKCι.2 and 
empty vector (Figure 3C), there was a >3-fold increase in the number 
of spheroids displaying PSAL compared with the scrambled control 
(Figure 3D). When the Ras-MDCK cells were treated with siPKCι.2 
and transfected with the resistant PKCι-cDNA the increase in sphe-
roids with PSAL was attenuated (<2-fold). Note that the biphasic/
threshold behaviour of the system is such that obtaining a precise, 
quantitative rescue is very difficult to achieve. Addition of PKCι to the 
scrambled control siRNA had little effect on the number of PSALs. 
Thus, a partial rescue of the siRNA-PKCι-induced phenotype with 
cDNA-PKCι was attained. These data are consistent with a model in 
which PKCι acts in cooperation with oncogenic Ras in determining 
transformed MDCK cell morphology.
PKCι depletion results in selective growth inhibition of oncogenic 
MDCK spheroids
In the multi-lumen, polarized morphology assay, the PKCι-depleted 
cysts were significantly smaller than control structures in keep-
ing with previous reports that have demonstrated decreased growth 
as a consequence of increased apoptosis upon aPKC inhibition or 
depletion (60,68). To quantify this decreased growth, multiple phase 
images were taken of each oncogenic spheroid condition following 
6 days growth in Matrigel (Figure 4A) and the mean cross-sectional 
area was calculated as an estimation of size (Figure 4B–G). All trans-
formed MDCK cells lines treated with scrambled control siRNA 
(siSCRAM) showed larger spheroids than the parental MDCK. 
Surprisingly, although the effect of PKCι knockdown on the multi-
lumen phenotype was limited to the H-Ras and ErbB2-MDCK sphe-
roids (Figure 2A and B), all oncogenic spheroids were decreased in 
size with the exception of the parental cell line, which was insensitive 
to any growth inhibition (Figure 4B–G).
The implication of the preceding data is that PKCι cooperates with 
various oncogenes to support 3D growth and that for a subset of these 
(Ras, ErbB2), PKCι protein and/or activity contributes to the loss of 
polarity. Furthermore, the recovery of polarity on reduction of PKCι 
in Ras- and ErbB2-transformed MDCK cells suggested that an over-
active PKCι was responsible for this aberrant behaviour. In contrast, 
in the parent cell, loss of PKCι has been reported to trigger loss of 
polarity suggesting that in fact the PKCι dependence displays thresh-
old behaviour (60,61,69). To test this, we manipulated gain and loss 
of function of PKCι in the parental MDCK cells. A conformationally 
normal, inactive, siRNA-resistant PKCι mutant (PKCι-D368N) was 
employed to generate a stable cell line. In addition, stable MDCK cells 
lines with constitutively active PKCι (PKCι-A120E), PKCι-WT and 
empty vector (GFP) were generated to examine the role of a graded 
increase in PKCι activity in MDCK lumenogenesis. Comparable lev-
els of exogenous and endogenous PKCι in the stable cells lines were 
confirmed by western blot (Supplementary Figure S3, available at 
Carcinogenesis Online). Following 6 days growth in Matrigel, normal 
lumenogenesis (~50% normal cysts) was seen for empty vector con-
trols and for PKCι-WT, although for the latter there was a non-signif-
icant increase in cyst size (Figure 5A and B). Notably, an increase in 
abnormal, multi-lumen cyst phenotype was seen following depletion 
of PKCι with siRNA (Figure 5C and D) and also in the PKCι-D368N-
expressing cells (Figure  5A and B). Unexpectedly, there was also 
an increase in multi-lumen formation on expression of the activated 
mutant PKCι-A120E-expressing cysts (Figure 5A and B).
This pattern of behaviour in response to manipulation of PKCι pro-
vides clear evidence for threshold behaviour—too little or too much 
triggering aberrant polarized morphology in 3D culture. The equiv-
alent levels of expression of the different mutants suggest that this 
behaviour is dependent on catalytic activity and not protein per se, 
consistent with the marked effect of the constitutively active pseudo-
substrate site mutant.
A novel PKCι inhibitor restores apical lumen formation
To assess this threshold, predicted catalytic behaviour of PKCι, we 
determined the response to the catalytic inhibitors CRT0066854, a 
recently described thieno[2,3-d]pyrimidine-based chemical inhibitor of 
aPKC (69), and Gö6983 (a pan PKC inhibitor) in H-Ras MDCK sphe-
roids. Inhibitors were added on the day of seeding a single cell suspen-
sion in Matrigel and then replenished on alternate days for 6 days. The 
inhibitor doses used for compounds were determined based on their 
individual, previously defined cellular IC50s (69,70). Both inhibitors 
phenocopied the siRNA-PKCι intervention resulting in the induction 
of apical lumen formation in the spheroids and a reduction in spheroid 
size (Figure 6). The maximal effect of Gö6983 was at 2 μM resulting in 
a 6-fold increase in PSALs (Figure 6A and C). The maximal proportion 
of spheroids with PSALs was seen with CRT0066854 at the lower dose 
of 1.2 μM (Figure 6B and D). Above these doses, there was increasing 
cell death making scoring of apical lumens unreliable. The response to 
these inhibitors is entirely consistent with a requirement for oncogene-
induced, elevated activity of PKCι to retain non-polarized proliferation.
Discussion
We have assessed the relationship between PKCι action in establish-
ing polarity in the 3D MDCK cyst cell model, with its role in the 
growth and aberrant morphology associated with oncogene transfor-
mation. Under normal conditions, it was confirmed that loss of PKCι 
function was associated with a loss of polarized MDCK cyst forma-
tion. However, it was also demonstrated that constitutive activation of 
PKCι also caused a loss of polarity. Evidently, there is a window in 
which a normal level of regulated PKCι needs to function to support 
polarization. The loss of polarity consequent to transformation by Ras 
and ErbB2, but not selected isoforms of PI3K, Raf or Src, was associ-
ated with a gain of PKCι activity, since knockdown or inhibition of 
catalytic activity could partially restore a polarized morphology. This 
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Fig. 2. The effect of PKCι knockdown on polarized morphogenesis of oncogenic MDCK spheroids. MDCK oncogenic variant cell lines were treated with two 
separate siRNA-PKCι (siPKCι1 and siPKCι2) and two scrambled controls (siSCRAM1 and siSCRAM2) for 24 h prior to culture in Matrigel for 6 days. (A) 
Representative single confocal images with phalloidin (red)-stained actin and Hoechst (blue)-identified nuclei. Scale bar represents 50 μm. (B) Quantification 
of number of PSALs. At least 100 spheroids were counted per condition and the mean and standard error of the mean of at least three separate experiments are 
presented. The statistical differences between PKCι knockdown conditions and the corresponding scrambled controls are shown; *P < 0.05; **P < 0.01; ***P < 
0.001. (C) PKCι protein depletion was confirmed in adherent cells 2 days after reseed (72 h after transfection) by western blot.
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indicates that Ras- and ErbB2-induced transformation upregulates the 
function of PKCι, pushing it beyond the threshold required to retain 
cyst polarity. In parental MDCK cysts, depletion of PKCι triggered 
loss of polarity. Although this may be a consequence of different 
PKCι-dependent signalling pathways in the different cell lines, in light 
of the data from the exogenous expression of PKCι activity mutants, 
this supports the role of required thresholds of PKCι abundance/activ-
ity. Given the multitude of effects of Ras and ErbB2 transformation 
on cell signalling, it is somewhat surprising that PKCι knockdown or 
chemical inhibition can acutely reverse (albeit partially) the abnormal 
non-polarized epithelial morphology but this is particularly interest-
ing in the context of potential therapeutic interventions.
Despite the clear PKCι-dependent multi-lumen formation, we did 
not find altered regulation of total PKCι levels or PKCι phospho-
rylation at the activation loop (pT403) or turn motif (pT555). Several 
groups have reported pT403/pT555 PKCι as an activity readout 
(67,68,71); however, because PKCs are typically constitutively phos-
phorylated it is not entirely surprising that altered phosphorylation 
is not detected (72). It is surmised that other modifications or more 
fleeting allosteric inputs to PKCι are engaged in this depolarising 
pathway. In this context, it is notable that despite a number of proposed 
mechanisms for Ras to influence PKCι there is no consensus mecha-
nism defined. Given the known aPKC-PI3K interplay (44,45,73), and 
that the pan-PI3K inhibitor, LY294002, has been reported to reverse 
the depolarized morphology of human mammary cell line spheroids 
(74), it was perhaps surprising that PKCι depletion/inhibition was 
unable to rescue the polarity of p110α-transformed spheroids. Given 
the evident sensitivity of PKCι to inhibition by the agents employed 
here, it can be surmised that the effects of p110α on morphology 
are triggered through one of the many other pathways dependent on 
phosphatidylinositol (3,4,5) trisphosphate. Reciprocally, the lack of 
connection between aPKCι and the PI3K pathway is indicative, in 
this context, of aPKCι control operating through its upstream regula-
tors (PDK1, TORC2, cdc42; see Introduction) in a manner that is not 
rate-limiting for phosphatidylinositol (3,4,5) trisphosphate produc-
tion and reflecting the finding that its direct interaction with anionic 
phospholipids is not unique to phosphatidylinositol (3,4,5) trisphos-
phate (75).
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Fig. 3. Rescue of siRNA-induced polarity phenotype by cDNA-PKCι. H-Ras-MDCK cells were sequentially transfected with siRNA-PKCι or scrambled control 
(siSCRAM) followed by siRNA-resistant PKCι-cDNA or empty vector (EV). Cells were reseeded in 6-well plates (A and B) or Matrigel (C and D) 24 h after second 
transfection. (A) The levels of endogenous PKCι knockdown and GFP-PKCι overexpression were determined by western blot 24 h after reseed. (B) Densitometry 
was performed on the resulting blots using ImageJ software. (C) The sequentially transfected cells were seeded in Matrigel and cultured for 6 days. Representative 
single confocal images of phalloidin (red)-stained actin and Hoechst (blue)-identified nuclei are shown. Scale bar represents 50 μm. (D) Quantification of the 
number of predominant single lumens is shown. At least 100 spheroids were counted per condition and the mean and standard error of the mean for three separate 
experiments are presented. The statistical differences of treatments compared with siSCRAM/EV control are shown: ns, not significant; **P < 0.01; ***P < 0.001.
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Fig. 4. The effect of PKCι knockdown on the size of oncogenic MDCK spheroids. MDCK oncogenic variant cell lines were treated with two separate siRNA-
PKCι (siPKCι1 and siPKCι2) and scrambled control (siSCRAM) for 24 h prior to culture in Matrigel for 6 days. (A) Representative single phase images are 
shown. Scale bar represents 50 μm. (B–G) Quantification of the normalized cross-sectional area of the spheroid lumens. At least 100 spheroids were counted per 
condition and the mean and standard error of the mean of at least three separate experiments are presented. Statistical significance of differences between PKCι 
knockdown conditions and the scrambled control is shown: *P < 0.05; **P < 0.01; ***P < 0.001.
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To our knowledge, oncogenic Ras has not previously been directly 
implicated as cooperating with aPKC in depolarized morphology in 
mammalian cells. The role in transformation; however, is more firmly 
established with both a Ras>PKCι>Rac1 axis (47,76) and synergism 
between Ras and PKCι for colony formation of ovarian cancer cells 
described (77). Furthermore, mice bitransgenic for oncogenic K-Ras 
and Cre-dependent loss of PKCι developed fewer lung tumours upon 
Cre-delivery (78). The cooperation between PKCι and ErbB2 seen in 
our study is consistent with the report in the MCF10a acini model, 
whereby genetic disruption of Par6 binding to aPKC rescued ErbB2-
induced loss of apical lumen formation and polarity (51). Intriguingly, 
the Oncomine dataset of human epithelial malignancies revealed that 
high levels of PKCι transcripts are concomitantly expressed with Ras 
and Her2 but not isoforms of PI3K, Raf or Src. This further suggests 
the target population for trials of PKCι inhibitors might usefully focus 
on Ras and/or ErbB2 mutant/upregulated tumours, a group that is 
Fig. 5. Manipulation of PKCι impacts on apical lumen formation in MDCK cells. MDCK cells stably transfected with empty vector (pEGFP), PKCι-WT or 
activity mutants; kinase dead (PKCι-D368N) or constitutively active (PKCι-A120E) were cultured in Matrigel for 6 days. (A) Representative single confocal 
images of actin staining (white) are presented. (B) Quantification of the number of PSALs. At least 100 spheroids were counted per condition and the mean and 
standard error of the mean of three separate experiments are presented. Statistical significance of any differences compared with the WT-PKCι are shown:  
***P < 0.001. (C) Representative western blot of three separate experiments showing the level of knockdown of endogenous PKCι by siRNA (siPKCι) or 
scrambled control (siSCRAM). (D) Representative single confocal images of actin staining (white) are presented. All scale bars represent 50 μm.
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estimated to encompass at least 30% of human tumours (COSMIC: 
www.sanger.ac.uk/genetics/CGP/cosmic, Gene Expression Atlas: 
www.ebi.ac.uk/arrayexpress).
The loss of polarized morphogenesis upon PKCι inhibition or 
depletion in normal cells questions whether PKCι is a suitable drug 
target. It has been proposed that disruption of cellular polarity facili-
tates oncogenic proliferation by releasing epithelial cells from struc-
tural or signaling constraints by the basement membrane (31,32). 
However, although PKCι depletion led to decreased growth in all 
transformed MDCK cell variants, in normal MDCK cells we did not 
observe any change in 3D cyst size despite the disrupted polarized 
morphogenesis. Our results suggest that PKCι has both growth and 
polarity functions depending on the cooperative oncogenic context. 
Therefore, if proliferation is inhibited, disruption in polarity may not 
be expected to be an oncogenic event in normal cells establishing an 
anticipated therapeutic index for PKCι inhibitors.
In conclusion, PKCι loss or gain of function disrupts normal-polar-
ized behaviour of MDCK cells, indicative of a threshold requirement 
for this kinase. In the context of cooperation with oncogenic Ras for 
the reversible depolarization of MDCK, this reflects hyperactivation 
(gain of function) of PKCι based on recovery following PKCι inhibi-
tion. This oncogene-dependent PKCι hyperactivation is pro-prolifera-
tive in 3D culture, providing compelling evidence that PKCι will be a 
good target for Ras mutant tumours.
Supplementary material
Supplementary Figures S1–S3 can be found at http://carcin.oxford-
journals.org/
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